Resources from the same session
LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Presenter: Gerhardt Attard
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast
LBA5_PR - A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Presenter: Karim Fizazi
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast
LBA6 - KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
Presenter: Jared Weiss
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast
LBA7 - Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Presenter: Yelena Janjigian
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA4 and LBA5
Presenter: Eleni Efstathiou
Session: Presidential symposium 2
Resources:
Slides
Webcast
Invited Discussant LBA7
Presenter: Florian Lordick
Session: Presidential symposium 2
Resources:
Slides
Webcast